CMS Off-Label Cancer Coverage Proposal Questioned By ASCO

CMS' proposal to cover clinical trials evaluating four colorectal cancer drugs in off-label uses is not a wise use of taxpayer dollars, the American Society of Clinical Oncology suggests in comments on the draft policy